Brain kinetics of methylphenidate (Ritalin) enantiomers after oral administration.

@article{Ding2004BrainKO,
  title={Brain kinetics of methylphenidate (Ritalin) enantiomers after oral administration.},
  author={Yu-Shin Ding and Samuel John Gatley and Panayotis K. Thanos and Colleen Shea and V{\'i}ctor M Garza and Youwen Xu and Pauline Carter and Payton King and Don Warner and Nicholas B Taintor and Daniel J. Park and Bea Pyatt and Joanna S. Fowler and Nora D. Volkow},
  journal={Synapse},
  year={2004},
  volume={53 3},
  pages={168-75}
}
Methylphenidate (MP) (Ritalin) is widely used for the treatment of attention deficit hyperactivity disorder (ADHD). It is a chiral drug, marketed as the racemic mixture of d- and l-threo enantiomers. Our previous studies (PET and microdialysis) in humans, baboons, and rats confirm the notion that pharmacological specificity of MP resides predominantly in the d-isomer. A recent report that intraperitoneally (i.p.) administered l-threo-MP displayed potent, dose-dependent inhibition of cocaine- or… CONTINUE READING
14 Citations
31 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Synthesis of the racemate and individual enantiomers of [11C]methylphenidate for studing presynaptic dopaminergic neurons with positron emission tomography

  • Y-S Ding, Y Sugano, JS Fowler, C. Salata
  • J Label Compds Radiopharm 34:889–997.
  • 1994
Highly Influential
3 Excerpts

The biological and clinical significance of single isomers

  • J. Rosenbaum
  • CNS SPECTRUMS: Int J Neuropsych Med 7:Supplement…
  • 2002
1 Excerpt

Method of dopamine inhibition using l-threomethylphenidate

  • B. Baldessarini
  • US patent US 6,221,883 B1.
  • 2001
1 Excerpt

Similar Papers

Loading similar papers…